Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia. Oya S, Ozawa H, Maehiro Y, Nakamura T, et al. Leuk Res 2023;130:107313.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Oya S, Ozawa H, Maehiro Y, Nakamura T, et al. Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia. Leuk Res 2023;130:107313.
PMID: 37207502